CSIMarket
 
Xtl Biopharmaceuticals Ltd   (XTLB)
Other Ticker:  
 
 
Price: $0.8800 $0.00 -0.441%
Day's High: $0.9699 Week Perf: -4.35 %
Day's Low: $ 0.85 30 Day Perf: 1.15 %
Volume (M): 3 52 Wk High: $ 1.54
Volume (M$): $ 2 52 Wk Avg: $1.02
Open: $0.85 52 Wk Low: $0.75



 Market Capitalization (Millions $) 542
 Shares Outstanding (Millions) 616
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 0
 Cash Flow (TTM) (Millions $) 3
 Capital Exp. (TTM) (Millions $) 0

Xtl Biopharmaceuticals Ltd
XTL Biopharmaceuticals Ltd is a publicly traded biopharmaceutical company based in Israel. It was founded in 1993 and focuses on the development of drugs to treat viral infections, autoimmune diseases, and cancer.

The company's flagship product is called hCDR1 (Edratide), which is a novel immunomodulatory drug designed to treat systemic lupus erythematosus (SLE) and other autoimmune diseases. The drug has completed two Phase II clinical trials and has shown promising results in reducing disease activity and improving patient quality of life.

XTL's other main product is called rHuEPO, which is a recombinant human erythropoietin used to treat anemia in patients with chronic renal failure. The drug has completed Phase II clinical trials and is in the process of being licensed.

In addition to these two products, XTL is also working on the development of drugs for the treatment of hepatitis C, HIV/AIDS, and solid tumor cancers. The company's drug development process involves identifying new targets, conducting pre-clinical studies, and testing the drugs in clinical trials.

The company has a strong intellectual property portfolio, with over 120 patents and patent applications both in the US and internationally. It has also entered into partnerships with other biotech and pharmaceutical companies, including Spanish drug maker Ferrer International, to develop and commercialize its products.

XTL has a highly experienced management team, including CEO Joshua Levine, who has over 30 years of experience in the biotech industry. The company is publicly traded on the Tel Aviv Stock Exchange (TASE) and on the NASDAQ under the ticker symbol XTLB.

Overall, XTL Biopharmaceuticals Ltd is a promising biotech company that has made significant strides in the development of novel drugs for the treatment of autoimmune diseases, viral infections, and cancer. Despite the challenges of drug development, the company has maintained a strong focus on innovation and is dedicated to improving the lives of patients around the world.


   Company Address: 5 Badner St. Ramat Gan 4365603
   Company Phone Number: 3-6116600   Stock Exchange / Ticker: NASDAQ XTLB
   XTLB is expected to report next financial results on March 21, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Leap Therapeutics Inc

Leap Therapeutics Inc Posts Operating Deficit of $14.82 Million in Latest Financial Report

Leap Therapeutics Inc, a major pharmaceutical preparations company, recently reported its financial results for the October to December 31, 2023 reporting season. While shareholders had not anticipated any significant changes, they were disappointed to observe an operating deficit of $14.82 million during this period. This represents a decline compared to the fourth quarter of 2022, when the operating deficit stood at $13.943 million.
Furthermore, the company recorded a shortfall of $12.465 million, a significant increase from the previous year's $12.102 million deficit. These figures highlight the challenging environment faced by Leap Therapeutics Inc during the specified timeframe.

Xbiotech Inc

XBITsn Holds Steady Revenue in Fourth Quarter of 2023

Xbiotech Inc., a leading biotechnology company, recently released its financial results for the fiscal period ending December 31, 2023. The company reported a loss of $0.15 per share, compared to $0.10 per share the previous year, while Income per Share improved from $0.24 to $0.00 per share from the previous quarter. Despite the losses, the company remains optimistic about its future growth prospects.
One interesting fact from the financial report is that Xbiotech Inc. realized a net shortfall of $4.635 million, which is higher than the $3.203 million reported a year ago. Additionally, the company also noted a shortfall of $24.56 million for the financial period 2023. Despite these challenges, the company is committed to innovation and advancing the frontiers of medical science.

Acurx Pharmaceuticals Inc

Acurx Pharmaceuticals Inc Faces Stock Plunge and Financial Contraction in Fiscal Fourth Quarter of 2023

Acurx Pharmaceuticals Inc, a Major Pharmaceutical Preparations company, has seen a significant drop in its stock price over the past year. The stock has dropped by -21.13% compared to a year ago, and by -35.48% in the past 90 days. Currently trading on the NASDAQ, the stock is -7.5% below its 52-week average.
The company recently reported its financial results for the period ending December 31, 2023, and shareholders have expressed concerns about the top-line performance. The operating shortfall for Acurx Pharmaceuticals Inc was at $-5.11459 million, which represents a contraction from $-3.260511 million in the fourth quarter of 2022. Analysts are closely watching to see if the company can improve its revenue numbers in the coming quarters.

Soligenix Inc

Soligenix Inc Narrows Fourth Quarter Shortfall 2.

As a financial journalist for the , I have been closely following the recent financial results of Major Pharmaceutical Preparations company, Soligenix Inc. The company's performance in the October to December 31, 2023 period has shown some improvement compared to the previous year.
In the fourth quarter of 2023, Soligenix Inc reported a net shortfall of $-1.820 million, a significant improvement from the $-11.901 million deficit in the same quarter a year ago. The company also managed to reduce its shortfall per share to $-0.17 from $-4.14 in the previous year, indicating progress in their financial performance.
Despite the positive changes, Soligenix Inc's revenue deteriorated by -11.55% from $0.95 million in the previous year. However, in the recent quarter, revenue surged by 87.682% from $0.13 million in the prior quarter, showing a promising trend for the company's future financial performance.

Eterna Therapeutics Inc

Eterna Therapeutics Inc Reports Revenue of $0.017 Million in Q4 2023 Financial Results

In the fourth quarter of 2023, Eterna Therapeutics Inc, a major pharmaceutical preparations company, disclosed revenue of $0.017 million, marking a slight increase from the previous year. However, the company also reported a net deficit of $-6.153 million for the same quarter, which was larger than the deficit of $-4.490 million in the previous year. This increase in deficit is concerning to analysts, especially as the level of accounts receivable has declined to $0.4 million, indicating a potential slowdown in demand for the company's products.
Furthermore, Eterna Therapeutics Inc indicated a net deficit of $-21.67 million for the fiscal year 2023, along with revenue of $0.07 million. Despite these challenges, the company has managed to decrease its deficit per share to $-4.08 from $-8.06 in the preceding fiscal year, showing some improvement in its financial performance.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com